Prevention and management of PARP inhibitor-related haematological toxicities in prostate cancer: French expert opinion using the Delphi method.

Date publication

septembre 2025

Journal

Therapeutic advances in medical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr SCHMITT Antonin

Tous les auteurs :
Cassuto O, Mathieu R, Helissey C, Schmitt A, Gobert A, Mourey L, Jovenin N, Bouteleux C, Joly F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40955339

Résumé

Haematological toxicities (anaemia, neutropenia and thrombocytopenia), a known class effect of poly-ADP ribose polymerase inhibitors (PARPi) may limit exposure to PARPi and therefore impact efficacy.

Mots clés

DELPHI consensus, PARP inhibitor, haematological toxicities, prostate cancer, toxicity management

Référence

Ther Adv Med Oncol. 2025 09 13;17:17588359251367308